

## SUMMARY OF PRODUCT CHARACTERISTICS

### VILDAGLIPTIN TABLET 50 MG (Vildagliptin)

#### 1. NAME OF THE MEDICINAL PRODUCT

VILDAGLIPTIN TABLET 50 MG

#### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

VILDAGLIPTIN TABLET 50 MG

Each tablet contains:

Vildagliptin.....50 mg

**Excipient with known effect:** Each tablet contains 94.50 mg lactose (anhydrous).

For full list of excipients, see **section 6.1**

#### 3. PHARMACEUTICAL FORM

Tablet

#### 4. CLINICAL PARTICULARS <sup>1</sup>

##### 4.1 Therapeutic indications

Vildagliptin is indicated in the treatment of type 2 diabetes mellitus in adults:

##### **As monotherapy**

- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.

##### **As dual oral therapy in combination with**

- metformin, in patients with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin,
- a sulphonylurea, in patients with insufficient glycaemic control despite maximal tolerated dose of a sulphonylurea and for whom metformin is inappropriate due to contraindications or intolerance,
- a thiazolidinedione, in patients with insufficient glycaemic control and for whom the use of a thiazolidinedione is appropriate.

##### **As triple oral therapy in combination with**

- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.

Vildagliptin is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control.

## **4.2 Posology and method of administration**

### Posology

#### *Adults*

When used as monotherapy, in combination with metformin, in combination with thiazolidinedione, in combination with metformin and a sulphonylurea, or in combination with insulin (with or without metformin), the recommended daily dose of vildagliptin is 100 mg, administered as one dose of 50 mg in the morning and one dose of 50 mg in the evening.

When used in dual combination with a sulphonylurea, the recommended dose of vildagliptin is 50 mg once daily administered in the morning. In this patient population, vildagliptin 100 mg daily was no more effective than vildagliptin 50 mg once daily.

When used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be considered to reduce the risk of hypoglycaemia.

Doses higher than 100 mg are not recommended.

If a dose of vildagliptin is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.

The safety and efficacy of vildagliptin as triple oral therapy in combination with metformin and a thiazolidinedione have not been established.

### Additional information on special populations

#### *Elderly (≥ 65 years)*

No dose adjustments are necessary in elderly patients (see also **section 5.2**).

#### *Renal impairment*

No dose adjustment is required in patients with mild renal impairment (creatinine clearance ≥ 50 ml/min). In patients with moderate or severe renal impairment or with end-stage renal disease (ESRD), the recommended dose of vildagliptin is 50 mg once daily (see also **sections 4.4 and 5.2**).

### *Hepatic impairment*

Vildagliptin should not be used in patients with hepatic impairment, including patients with pre-treatment alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3x the upper limit of normal (ULN) (see also **sections 4.4 and 5.2**).

### *Paediatric population*

Vildagliptin is not recommended for use in children and adolescents (< 18 years). The safety and efficacy of vildagliptin in children and adolescents (< 18 years) have not been established. No data are available.

### Method of administration

Oral use

Vildagliptin can be administered with or without a meal (see also **section 5.2**).

## **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients.

## **4.4 Special warnings and precautions for use**

### General

Vildagliptin is not a substitute for insulin in insulin-requiring patients. Vildagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

### Renal impairment

There is limited experience in patients with ESRD on haemodialysis. Therefore vildagliptin should be used with caution in these patients (see also **sections 4.2 and 5.2**).

### Hepatic impairment

Vildagliptin should not be used in patients with hepatic impairment, including patients with pre-treatment ALT or AST > 3x ULN (see also **sections 4.2 and 5.2**).

### Liver enzyme monitoring

Rare cases of hepatic dysfunction (including hepatitis) have been reported. In these cases, the patients were generally asymptomatic without clinical sequelae and liver function test results returned to normal after discontinuation of treatment. Liver function tests should be performed prior to the initiation of treatment with vildagliptin in order to know the patient's baseline value. Liver function should be monitored during treatment with vildagliptin at threemonth intervals during the first year and periodically thereafter. Patients who develop increased transaminase levels should be monitored with a second liver

function evaluation to confirm the finding and be followed thereafter with frequent liver function tests until the abnormality(ies) return(s) to normal. Should an increase in AST or ALT of 3x ULN or greater persist, withdrawal of vildagliptin therapy is recommended.

Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue vildagliptin.

Following withdrawal of treatment with vildagliptin and LFT normalisation, treatment with vildagliptin should not be reinitiated.

#### Cardiac failure

Reported clinical study of vildagliptin in patients with New York Heart Association (NYHA) functional class I-III showed that treatment with vildagliptin was not associated with a change in left-ventricular function or worsening of pre-existing congestive heart failure (CHF) versus placebo. Clinical experience in patients with NYHA functional class III treated with vildagliptin is still limited and results are inconclusive.

There is no experience of vildagliptin use in clinical studies in patients with NYHA functional class IV and therefore use is not recommended in these patients.

#### Skin disorders

Skin lesions, including blistering and ulceration have been reported in extremities of monkeys in non-clinical toxicology studies (see **section 5.3**). Although skin lesions were not observed at an increased incidence in reported clinical studies, there was limited experience in patients with diabetic skin complications.

Furthermore, there have been post-marketing reports of bullous and exfoliative skin lesions.

Therefore, in keeping with routine care of the diabetic patient, monitoring for skin disorders, such as blistering or ulceration, is recommended.

#### Acute pancreatitis

Use of vildagliptin has been associated with a risk of developing acute pancreatitis. Patients should be informed of the characteristic symptom of acute pancreatitis.

If pancreatitis is suspected, vildagliptin should be discontinued; if acute pancreatitis is confirmed, vildagliptin should not be restarted. Caution should be exercised in patients with a history of acute pancreatitis.

#### Hypoglycaemia

Sulphonylureas are known to cause hypoglycaemia. Patients receiving vildagliptin in combination with a sulphonylurea may be at risk for hypoglycaemia. Therefore, a lower dose of sulphonylurea may be considered to reduce the risk of hypoglycaemia.

### Excipients

The tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

## **4.5 Interaction with other medicinal products and other forms of interaction**

Vildagliptin has a low potential for interactions with co-administered medicinal products. Since vildagliptin is not a cytochrome P (CYP) 450 enzyme substrate and does not inhibit or induce CYP 450 enzymes, it is not likely to interact with active substances that are substrates, inhibitors or inducers of these enzymes.

### Combination with pioglitazone, metformin and glyburide

Results from studies conducted with these oral antidiabetics have reported no clinically relevant pharmacokinetic interactions.

### Digoxin (Pgp substrate), warfarin (CYP2C9 substrate)

Clinical studies performed with healthy subjects have reported no clinically relevant pharmacokinetic interactions. However, this has not been established in the target population.

### Combination with amlodipine, ramipril, valsartan or simvastatin

Drug-drug interaction studies in healthy subjects were reported with amlodipine, ramipril, valsartan and simvastatin. In these studies, no clinically relevant pharmacokinetic interactions were reported after co-administration with vildagliptin.

### Combination with ACE-inhibitors

There may be an increased risk of angioedema in patients concomitantly taking ACE-inhibitors (see **section 4.8**).

As with other oral antidiabetic medicinal products the hypoglycaemic effect of vildagliptin may be reduced by certain active substances, including thiazides, corticosteroids, thyroid products and sympathomimetics.

## **4.6 Fertility, pregnancy and lactation**

### Pregnancy

There are no adequate data from the use of vildagliptin in pregnant women. Reported studies in animals have shown reproductive toxicity at high doses (see **section 5.3**). The potential risk for humans is unknown. Due to lack of human data, vildagliptin should not be used during pregnancy.

### Lactation

It is unknown whether vildagliptin is excreted in human milk. Reported animal studies have shown excretion of vildagliptin in milk. Vildagliptin should not be used during breast-feeding.

### Fertility

No studies on the effect on human fertility have been reported for vildagliptin (see **section 5.3**).

### **4.7 Effects on ability to drive and use machines**

No studies on the effects on the ability to drive and use machines have been reported. Patients who experience dizziness as an adverse reaction should avoid driving vehicles or using machines.

### **4.8 Undesirable effects**

#### Summary of the safety profile

Safety data were obtained from patients exposed to vildagliptin at a daily dose of 50 mg (once daily) or 100 mg (50 mg twice daily or 100 mg once daily) in reported controlled studies of at least 12 weeks duration. Patients received vildagliptin as monotherapy or vildagliptin in combination with another medicinal product.

The majority of adverse reactions in these studies were mild and transient, not requiring treatment discontinuations. No association has been reported between adverse reactions and age, ethnicity, duration of exposure or daily dose.

Rare cases of hepatic dysfunction (including hepatitis) have been reported. In these cases, the patients were generally asymptomatic without clinical sequelae and liver function returned to normal after discontinuation of treatment. In reported data from controlled monotherapy and add-on therapy studies of up to 24 weeks in duration, the incidence of ALT or AST elevations  $\geq 3x$  ULN (classified as present on at least 2 consecutive measurements or at the final on-treatment visit) was 0.2%, 0.3% and 0.2% for vildagliptin 50 mg once daily, vildagliptin 50 mg twice daily and all comparators, respectively. These elevations in transaminases were generally asymptomatic, nonprogressive in nature and not associated with cholestasis or jaundice.

Rare cases of angioedema have been reported on vildagliptin at a similar rate to controls. A greater proportion of cases were reported when vildagliptin was administered in combination with an angiotensin converting enzyme inhibitor (ACE-Inhibitor). The majority of events were mild in severity and resolved with ongoing vildagliptin treatment.

#### Tabulated list of adverse reactions

Adverse reactions reported in patients who received vildagliptin in doubleblind studies as monotherapy and add-on therapies are listed below for each indication by system organ class and absolute frequency. Frequencies are defined as very common ( $\geq 1/10$ ), common ( $\geq 1/100$  to  $< 1/10$ ), uncommon ( $\geq 1/1,000$  to  $< 1/100$ ), rare ( $\geq 1/10,000$  to  $< 1/1,000$ ), very rare ( $< 1/10,000$ ), not known (cannot be estimated from

the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

*Combination with metformin*

**Table 1 Adverse reactions reported in patients who received vildagliptin 100 mg daily in combination with metformin in double-blind studies**

<b>Metabolism and nutrition disorders</b>	
Common	Hypoglycaemia
<b>Nervous system disorders</b>	
Common	Tremor
Common	Headache
Common	Dizziness
Uncommon	Fatigue
<b>Gastrointestinal disorders</b>	
Common	Nausea

*Description of selected adverse reactions*

In controlled clinical studies with the combination of vildagliptin 100 mg daily + metformin, no withdrawal due to adverse reactions was reported in either the vildagliptin 100 mg daily + metformin or the placebo + metformin treatment groups.

In reported clinical studies, the incidence of hypoglycaemia was common in patients receiving vildagliptin 100 mg daily in combination with metformin (1%) and uncommon in patients receiving placebo + metformin (0.4%). No severe hypoglycaemic events were reported in the vildagliptin arms.

In reported clinical studies, weight did not change from baseline when vildagliptin 100 mg daily was added to metformin (+0.2 kg and -1.0 kg for vildagliptin and placebo, respectively).

Reported clinical studies of up to more than 2 years' duration did not show any additional safety signals or unforeseen risks when vildagliptin was added on to metformin.

*Combination with a sulphonylurea*

**Table 2 Adverse reactions reported in patients who received vildagliptin 50 mg in combination with a sulphonylurea in double-blind studies**

<b>Infections and infestations</b>	
Very rare	Nasopharyngitis
<b>Metabolism and nutrition disorders</b>	
Common	Hypoglycaemia
<b>Nervous system disorders</b>	
Common	Tremor
Common	Headache
Common	Dizziness
Common	Asthenia
<b>Gastrointestinal disorders</b>	
Uncommon	Constipation

Description of selected adverse reactions

In reported controlled clinical studies with the combination of vildagliptin 50 mg + a sulphonylurea, the overall incidence of withdrawals due to adverse reactions was 0.6% in the vildagliptin 50 mg + sulphonylurea vs. 0% in the placebo + sulphonylurea treatment group.

In reported clinical studies, the incidence of hypoglycaemia when vildagliptin 50 mg once daily was added to glimepiride was 1.2% versus 0.6% for placebo + glimepiride. No severe hypoglycaemic events were reported in the vildagliptin arms.

In reported clinical studies, weight did not change from baseline when vildagliptin 50 mg daily was added to glimepiride (-0.1 kg and -0.4 kg for vildagliptin and placebo, respectively).

*Combination with a thiazolidinedione*

**Table 3 Adverse reactions reported in patients who received vildagliptin 100 mg daily in combination with a thiazolidinedione in double-blind studies**

<b>Metabolism and nutrition disorders</b>
---

Common	Weight increase
Uncommon	Hypoglycaemia
<b>Nervous system disorders</b>	
Uncommon	Headache
Uncommon	Asthenia
<b>Vascular disorders</b>	
Common	Oedema peripheral

Description of selected adverse reactions

In controlled clinical studies with the combination of vildagliptin 100 mg daily+ a thiazolidinedione, no withdrawal due to adverse reactions was reported in either the vildagliptin 100 mg daily + thiazolidinedione or the placebo + thiazolidinedione treatment groups.

In reported clinical studies, the incidence of hypoglycaemia was uncommon in patients receiving vildagliptin + pioglitazone (0.6%) but common in patients receiving placebo + pioglitazone (1.9%). No severe hypoglycaemic events were reported in the vildagliptin arms.

In the reported pioglitazone add-on study, the absolute weight increases with placebo, vildagliptin 100 mg daily were 1.4 and 2.7 kg, respectively.

The incidence of peripheral oedema when vildagliptin 100 mg daily was added to a maximum dose of background pioglitazone (45 mg once daily) has been reported to be 7.0%, compared to 2.5% for background pioglitazone alone.

*Monotherapy*

**Table 4 Adverse reactions reported in patients who received vildagliptin 100 mg daily as monotherapy in double-blind studies**

<b>Infections and infestations</b>	
Very rare	Upper respiratory tract infection
Very rare	Nasopharyngitis
<b>Metabolism and nutrition disorders</b>	
Uncommon	Hypoglycaemia
<b>Nervous system disorders</b>	
Common	Dizziness
Uncommon	Headache
<b>Vascular disorders</b>	

Uncommon	Oedema peripheral
<b>Gastrointestinal disorders</b>	
Uncommon	Constipation
<b>Musculoskeletal and connective tissue disorders</b>	
Uncommon	Arthralgia

Description of selected adverse reactions

In addition, in reported controlled monotherapy studies with vildagliptin the overall incidence of withdrawals due to adverse reactions was no greater for patients treated with vildagliptin at doses of 100 mg daily (0.3%) than for placebo (0.6%) or comparators (0.5%).

In comparative controlled monotherapy studies, hypoglycaemia was uncommon, reported in 0.4% of patients treated with vildagliptin 100 mg daily compared to 0.2% of patients in the groups treated with an active comparator or placebo, with no serious or severe events reported.

In reported clinical studies, weight did not change from baseline when vildagliptin 100 mg daily was administered as monotherapy (-0.3 kg and -1.3 kg for vildagliptin and placebo, respectively).

Reported clinical studies of up to 2 years' duration did not show any additional safety signals or unforeseen risks with vildagliptin monotherapy.

*Combination with metformin and a sulphonylurea*

**Table 5 Adverse reactions reported in patients who received vildagliptin 50 mg twice daily in combination with metformin and a sulphonylurea**

<b>Metabolism and nutritional disorders</b>	
Common	Hypoglycaemia
<b>Nervous system disorders</b>	
Common	Dizziness, tremor
<b>Skin and subcutaneous tissue disorders</b>	
Common	Hyperhidrosis
<b>General disorders and administration site conditions</b>	
Common	Asthenia

Description of selected adverse reactions

There were no withdrawals due to adverse reactions reported in the vildagliptin + metformin + glimepiride treatment group versus 0.6% in the placebo + metformin + glimepiride treatment group.

The incidence of hypoglycaemia was common in both treatment groups (5.1% for the vildagliptin + metformin + glimepiride group versus 1.9% for the placebo + metformin + glimepiride group). A severe hypoglycaemic event was reported in the vildagliptin group.

At the end of the reported study, effect on mean body weight was neutral (+0.6 kg in the vildagliptin group and -0.1 kg in the placebo group).

*Combination with insulin*

**Table 6 Adverse reactions reported in patients who received vildagliptin 100 mg daily in combination with insulin (with or without metformin) in double-blind studies**

<b>Metabolism and nutrition disorders</b>	
Common	Decreased blood glucose
<b>Nervous system disorders</b>	
Common	Headache, chills
<b>Gastrointestinal disorders</b>	
Common	Nausea, gastro-oesophageal reflux disease
Uncommon	Diarrhoea, flatulence

Description of selected adverse reactions

In reported controlled clinical studies using vildagliptin 50 mg twice daily in combination with insulin, with or without concomitant metformin, the overall incidence of withdrawals due to adverse reactions was 0.3% in the vildagliptin treatment group and there were no withdrawals in the placebo group.

The incidence of hypoglycaemia was similar in both treatment groups (14.0% in the vildagliptin group vs 16.4% in the placebo group).

At the end of the reported study, effect on mean body weight was neutral (+0.6 kg change from baseline in the vildagliptin group and no weight change in the placebo group).

## Post-marketing experience

**Table 7 Post-marketing adverse reactions**

<b>Gastrointestinal disorders</b>	
Not known	Pancreatitis
<b>Hepatobiliary disorders</b>	
Not known	Hepatitis (reversible upon discontinuation of the medicinal product) Abnormal liver function tests (reversible upon discontinuation of the medicinal product)
<b>Musculoskeletal and connective tissue disorders</b>	
Not known	Myalgia
<b>Skin and subcutaneous tissue disorders</b>	
Not known	Urticaria Exfoliative and bullous skin lesions, including bullous pemphigoid

**Reporting of suspected adverse reactions:** Healthcare professionals are requested to report any suspected adverse reactions via pharmacy and poisons board, Pharmacovigilance Electronic Reporting System (PvERS) <https://pv.pharmacyboardkenya.org>

### **4.9 Overdose**

Information regarding overdose with vildagliptin is limited.

#### Symptoms

Information on the likely symptoms of overdose was taken from a reported rising dose tolerability study in healthy subjects given vildagliptin for 10 days. At 400 mg, there were reported cases of muscle pain, and individual cases of mild and transient paraesthesia, fever, oedema and a transient increase in lipase levels. At 600 mg, a subject experienced oedema of the feet and hands, and increases in creatine phosphokinase (CPK), aspartate aminotransferase (AST), C-reactive protein (CRP) and myoglobin levels. Few other subjects experienced oedema of the feet, with paraesthesia. All symptoms and laboratory abnormalities resolved without treatment after discontinuation of the study medicinal product.

#### Management

In the event of an overdose, supportive management is recommended. Vildagliptin cannot be removed by haemodialysis. However, the major hydrolysis metabolite (LAY 151) can be removed by haemodialysis.

## 5. PHARMACOLOGICAL PROPERTIES <sup>1</sup>

### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Drugs used in diabetes, dipeptidyl peptidase 4 (DPP-4) inhibitors, ATC code: A10BH02

Vildagliptin, a member of the islet enhancer class, is a potent and selective DPP-4 inhibitor.

#### Mechanism of action

The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).

#### Pharmacodynamic effects

By increasing the endogenous levels of these incretin hormones, vildagliptin enhances the sensitivity of beta cells to glucose, resulting in improved glucose-dependent insulin secretion. Treatment with vildagliptin 50-100 mg daily in patients with type 2 diabetes significantly improved markers of beta cell function including HOMA- $\beta$  (Homeostasis Model Assessment- $\beta$ ), proinsulin to insulin ratio and measures of beta cell responsiveness from the frequently-sampled meal tolerance test. In non-diabetic (normal glycaemic) individuals, vildagliptin does not stimulate insulin secretion or reduce glucose levels.

By increasing endogenous GLP-1 levels, vildagliptin also enhances the sensitivity of alpha cells to glucose, resulting in more glucose-appropriate glucagon secretion.

The enhanced increase in the insulin/glucagon ratio during hyperglycaemia due to increased incretin hormone levels results in a decrease in fasting and postprandial hepatic glucose production, leading to reduced glycaemia.

The known effect of increased GLP-1 levels delaying gastric emptying is not observed with vildagliptin treatment.

### 5.2 Pharmacokinetic properties

#### Absorption

Following oral administration in the fasting state, vildagliptin is rapidly absorbed, with peak plasma concentrations observed at 1.7 hours. Food slightly delays the time to peak plasma concentration to 2.5 hours, but does not alter the overall exposure (AUC). Administration of vildagliptin with food resulted in a decreased  $C_{max}$  (19%). However, the magnitude of change is not clinically significant, so that vildagliptin can be given with or without food.

The absolute bioavailability is 85%.

### Distribution

The plasma protein binding of vildagliptin is low (9.3%) and vildagliptin distributes equally between plasma and red blood cells. The mean volume of distribution of vildagliptin at steady-state after intravenous administration ( $V_{ss}$ ) is 71 litres, suggesting extravascular distribution.

### Biotransformation

Metabolism is the major elimination pathway for vildagliptin in humans, accounting for 69% of the dose. The major metabolite (LAY 151) is pharmacologically inactive and is the hydrolysis product of the cyano moiety, accounting for 57% of the dose, followed by the glucuronide (BQS867) and the amide hydrolysis products (4% of dose). Reported *in vitro* data in human kidney microsomes suggest that the kidney may be one of the major organs contributing to the hydrolysis of vildagliptin to its major inactive metabolite, LAY151. DPP-4 contributes partially to the hydrolysis of vildagliptin based on reported *in vivo* study using DPP-4 deficient rats. Vildagliptin is not metabolised by CYP 450 enzymes to any quantifiable extent. Accordingly, the metabolic clearance of vildagliptin is not anticipated to be affected by comedications that are CYP 450 inhibitors and/or inducers. *In vitro* studies reported that vildagliptin does not inhibit/induce CYP 450 enzymes. Therefore, vildagliptin is not likely to affect metabolic clearance of comedications metabolised by CYP 1A2, CYP 2C8, CYP 2C9, CYP 2C19, CYP 2D6, CYP 2E1 or CYP 3A4/5.

### Elimination

Following oral administration of [ $^{14}$ C] vildagliptin, approximately 85% of the dose was excreted into the urine and 15% of the dose is recovered in the faeces. Renal excretion of the unchanged vildagliptin accounted for 23% of the dose after oral administration. After intravenous administration to healthy subjects, the total plasma and renal clearances of vildagliptin are 41 and 13 l/h, respectively. The mean elimination half-life after intravenous administration is approximately 2 hours. The elimination half-life after oral administration is approximately 3 hours.

### Linearity / non-linearity

The  $C_{max}$  for vildagliptin and the area under the plasma concentrations versus time curves (AUC) increased in an approximately dose proportional manner over the therapeutic dose range.

### Characteristics in specific groups of patients

#### *Gender*

No clinically relevant differences in the pharmacokinetics of vildagliptin were reported between male and female healthy subjects within a wide range of age and body mass index (BMI). DPP-4 inhibition by vildagliptin is not affected by gender.

### *Elderly*

In healthy elderly subjects ( $\geq 70$  years), the overall exposure of vildagliptin (100 mg once daily) was increased by 32%, with an 18% increase in peak plasma concentration as compared to young healthy subjects (18-40 years). These changes are, however, not considered to be clinically relevant. DPP-4 inhibition by vildagliptin is not affected by age.

### *Hepatic impairment*

The effect of impaired hepatic function on the pharmacokinetics of vildagliptin has been reported in patients with mild, moderate and severe hepatic impairment based on the Child-Pugh scores (ranging from 6 for mild to 12 for severe) in comparison with healthy subjects. It has been reported that the exposure to vildagliptin after a single dose in patients with mild and moderate hepatic impairment was decreased (20% and 8%, respectively), while the exposure to vildagliptin for patients with severe impairment was increased by 22%. The maximum change (increase or decrease) in the exposure to vildagliptin is  $\sim 30\%$ , which is not considered to be clinically relevant. There was no correlation between the severity of the hepatic disease and changes in the exposure to vildagliptin.

### *Renal impairment*

A multiple-dose, open-label study evaluated the pharmacokinetics of the lower therapeutic dose of vildagliptin (50 mg once daily) in patients with varying degrees of chronic renal impairment defined by creatinine clearance (mild: 50 to  $<80$  ml/min, moderate: 30 to  $<50$  ml/min and severe:  $<30$  ml/min) compared to normal healthy control subjects.

Vildagliptin AUC increased on average 1.4, 1.7 and 2-fold in patients with mild, moderate and severe renal impairment, respectively, compared to normal healthy subjects. AUC of the metabolites LAY151 and BQS867 increased on average about 1.5, 3 and 7-fold in patients with mild, moderate and severe renal impairment, respectively. Limited data from patients with end stage renal disease (ESRD) indicate that vildagliptin exposure is similar to that in patients with severe renal impairment. LAY151 concentrations were approximately 23-fold higher than in patients with severe renal impairment.

Vildagliptin was removed by haemodialysis to a limited extent (3% over a 3-4 hour haemodialysis session starting 4 hours post dose).

### *Ethnic group*

Limited data suggest that race does not have any major influence on vildagliptin pharmacokinetics.

## **5.3 Preclinical safety data**

Intra-cardiac impulse conduction delays were reported in dogs with a no-effect dose of 15 mg/kg (7-fold human exposure based on  $C_{max}$ ).

Accumulation of foamy alveolar macrophages in the lung was reported in rats and mice. The no-effect dose in rats was 25 mg/kg (5-fold human exposure based on AUC) and in mice 750 mg/kg (142-fold human exposure).

Gastrointestinal symptoms, particularly soft faeces, mucoid faeces, diarrhoea and, at higher doses, faecal blood were reported in dogs. A no-effect level was not established.

Vildagliptin was not mutagenic in conventional *in vitro* and *in vivo* tests for genotoxicity.

A fertility and early embryonic development study in rats reported no evidence of impaired fertility, reproductive performance or early embryonic development due to vildagliptin. Embryo-foetal toxicity was evaluated in rats and rabbits. An increased incidence of wavy ribs was reported in rats in association with reduced maternal body weight parameters, with a no-effect dose of 75 mg/kg (10-fold human exposure). In rabbits, decreased foetal weight and skeletal variations indicative of developmental delays were noted only in the presence of severe maternal toxicity, with a no-effect dose of 50 mg/kg (9-fold human exposure). A pre- and postnatal development study was reported in rats. Findings were only reported in association with maternal toxicity at  $\geq 150$  mg/kg and included a transient decrease in body weight and reduced motor activity in the F1 generation.

A two-year carcinogenicity study was reported in rats at oral doses up to 900 mg/kg (approximately 200 times human exposure at the maximum recommended dose). No increases in tumour incidence attributable to vildagliptin were reported. Another two-year carcinogenicity study was reported in mice at oral doses up to 1,000 mg/kg. An increased incidence of mammary adenocarcinomas and haemangiosarcomas was reported with a noeffect dose of 500 mg/kg (59-fold human exposure) and 100 mg/kg (16-fold human exposure), respectively. The increased incidence of these tumours in mice is considered not to represent a significant risk to humans based on the lack of genotoxicity of vildagliptin and its principal metabolite, the occurrence of tumours only in one species and the high systemic exposure ratios at which tumours were reported.

In a reported 13-week toxicology study in cynomolgus monkeys, skin lesions have been recorded at doses  $\geq 5$  mg/kg/day. These were consistently located on the extremities (hands, feet, ears and tail). At 5 mg/kg/day (approximately equivalent to human AUC exposure at the 100 mg dose), only blisters were reported. They were reversible despite continued treatment and were not associated with histopathological abnormalities. Flaking skin, peeling skin, scabs and tail sores with correlating histopathological changes were reported at doses  $\geq 20$

mg/kg/day (approximately 3 times human AUC exposure at the 100 mg dose). Necrotic lesions of the tail were reported at  $\geq 80$  mg/kg/day. Skin lesions were not reversible in the monkeys treated at 160 mg/kg/day during a 4-week recovery period.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients:**

**Excipients:** Lactose anhydrous, microcrystalline cellulose, sodium starch glycolate, magnesium stearate

### **6.2 Incompatibilities Not Applicable**

### **6.3 Shelf life 36 Months**

### **6.4 Special precautions for storage** Keep this medicines out of the reach of children. Store below 30°C. Protect from moisture

### **6.5 Nature and contents of container** Cold form Blister pack

### **6.6 Special precautions for disposal and other handling** No special requirements for disposal

## **7. MARKETING AUTHORIZATION HOLDER**

Sun Pharmaceutical Industries Limited,  
Sun House, Plot No. 201 B/1  
Western Express Highway,  
Goregaon (East), Mumbai, India

### **8. MARKETING AUTHORISATION NUMBER            Not Available**

### **9. DATE            OF            FIRST            AUTHORISATION**

15<sup>TH</sup> DEC, 2025

### **10. DATE OF REVISION OF THE TEXT**

15<sup>TH</sup> DEC, 2025